3. Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE: JNJ) ranks third because it combines a fast-growing innovative-medicine business with one of the world’s largest medical-technology platforms. Unlike a pure pharmaceutical company, it does not need every earnings cycle to depend entirely on prescription-drug sales. Its medical devices are used in surgery, cardiovascular care, orthopedics and vision, while its medicine portfolio spans oncology, immunology and neuroscience. This structure creates several independent revenue engines and makes Johnson & Johnson (NYSE: JNJ) one of the most diversified healthcare stocks available to public-market investors.
The company delivered second-quarter 2026 sales of $25.31 billion, an increase of 6.6%, while adjusted earnings reached $2.90 per share. Management raised its full-year outlook and now expects reported sales of approximately $101.1 billion at the midpoint and adjusted earnings of approximately $11.68 per share. Innovative Medicine generated $16.38 billion in quarterly sales, rising 7.8% on a reported basis, while MedTech revenue increased 4.5% to $8.93 billion. The company is therefore not merely large; it continues producing meaningful growth despite already operating at an enormous scale.
Oncology has become the most important driver. Worldwide oncology sales increased 17.3% to approximately $7.41 billion during the quarter. Darzalex revenue rose 18.9% to $4.21 billion, while Carvykti sales climbed 49.4% to $657 million. Teclistamab and the Rybrevant-Lazcluze combination also contributed to growth. These products are helping offset declining sales of older medicines such as Stelara, Remicade, Imbruvica and Zytiga. Johnson & Johnson (NYSE: JNJ) also continues advancing Tremfya, Spravato and Caplyta, giving the medicine division growth opportunities outside oncology. The company earns third place because it offers a rare blend of pharmaceutical innovation, medical-device diversification, cash-flow strength and rising guidance. It may not match the explosive obesity-driven growth of the No. 1 company, but it is arguably one of the most durable healthcare investments in the ranking.
Click next to see the following stock...
